Home » Asthma And COPD Drugs Market

Asthma And COPD Drugs Market By Drug Type (Anti-Inflammatory Drugs, Bronchodilator Monotherapy, Combination Drugs, Pipeline Analysis) – Growth, Future Prospects And Competitive Analysis 2017 – 2025

Price: $4999

Published: | Report ID: 2348 | Report Format : PDF

Market Insights

Asthma is a chronic respiratory disease that causes inflammation and narrowing of the airways. COPD (Chronic Obstructive Pulmonary Disease) is a lung disease that makes breathing difficult, including chronic bronchitis and emphysema, and that gets worse with time. COPD is one of the leading causes of mortality and morbidity worldwide, with a prevalence rate of 5–13%.

Increases in smoking rates and air population are directly proportional to prevalence rates, particularly in developing countries. New pharmacologic options for asthma and COPD have been investigated by focusing on specific biological mechanisms and understanding the pathogenesis of these diseases. As a result, the introduction of new drugs may provide better treatment options. The generic entry of a drug might affect the market, slowing its growth of the market. With key players innovating novel combination therapies and using biologics, personalized treatment would drive the asthma and COPD drug market.

The report titled “Asthma and COPD Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into overall asthma and COPD drug market, along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on types of drugs and different geographies. The drug types studied for analyzing the overall global asthma and COPD drugs market are majorly segmented into anti-inflammatory drugs, bronchodilator monotherapy, and combination drugs. Anti-inflammatory drugs include corticosteroids, anti-leukotrienes, and monoclonal antibodies. Bronchodilator monotherapy includes short-acting beta2-agonists (SABAs) and long-acting beta2-agonists (LABAs), and anticholinergics.

Geographically, global asthma and COPD drugs market is studied for the following regional markets:

      • North America
        • U.S.
        • Canada
      • Europe
        • Germany
        • France
        • Italy
        • U.K.
        • Russia
        • Rest of Europe
      • Asia-Pacific
        • India
        • China
        • Japan
        • Rest of Asia-Pacific
      • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
      • Middle East and Africa
        • GCC Countries
        • South Africa
        • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in global asthma and COPD drugs market.

Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the competitive scenario of global asthma and COPD drugs market. This report concludes with a company profiles section that highlights major information about the key players engaged in global asthma and COPD drugs market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Based on the type of drug, global asthma and COPD market is segmented as follows:

      • Anti-inflammatory drugs
      • Corticosteroids
      • Anti-Leukotrienes
      • Monoclonal antibodies
      • Bronchodilator monotherapy
      • Short-acting beta2-agonists (SABAs)
      • Long-acting beta2-agonists (LABAs)
      • Anticholinergics
      • Combination drugs

Currently, treatment available for asthma and COPD includes anti-inflammatory drugs, bronchodilator monotherapy, and combination therapy, of which combination therapy dominates the market. The most preferred combination for treatment is a long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination that includes Symbicort (AstraZeneca) and Advair (GlaxoSmithKline).

The combination is most preferred due to its better efficacy, convenient delivery mechanism, and decreased side effects. Singulair, Seretide, and Spiriva have commonly used medications for the treatment of asthma and COPD in the US and Europe. Further, an increase in the use of corticosteroids in combination with bronchodilators would drive the treatment market for asthma and COPD. Recent treatments such as combination products once daily and monoclonal antibodies will create new growth opportunities for the market.

There are many studies in various stages of development in the pipeline. Pharmaceutical companies have been investing heavily in the research and development of new biologics with the help of biotechnology, which would create immense market opportunities for the sustainable development of asthma and COPD markets. The only biologic currently available for the treatment of asthma is Novartis’ immunoglobulin E (IgE) inhibitor Xolair (omalizumab). Benralizumab Astrazenca’s first biologic is expected to enter the market next year, which would create a new wave for the use of biologics for the treatment of asthma.

For the purpose of this study, global asthma and COPD market are geographically categorized into:

      • North America
      • Europe
      • Asia Pacific
      • Latin America (LATAM)
      • Middle East and Africa (MEA)

At present, North America dominates global asthma and COPD market, followed by the European market. The major drivers for the North American market are the rising prevalence of asthma and COPD, technological advancements in treatment, a delay in the influx of generics, and a strong pipeline of novel therapies. The prevalence of asthma and COPD is increasing in developed countries due to factors such as smoking, sedentary lifestyles, obesity, genetic factors, etc.

The rise in demand for treatment and the high cost of treatment also contribute to market growth. Asia-Pacific is anticipated to be the fastest-growing market during the forecast period. In emerging countries such as China, India, and others, there is an increase in the incidences of asthma and other respiratory diseases due to rising pollution, urbanization, sedentary lifestyles, and prolonged life expectancy.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Asthma and COPD Market Portraiture
2.2 Global Asthma and COPD Market Share, by Drug type, 2016 Vs 2025 (Value %)
2.3 Global Asthma and COPD Market, by Geography, 2016 (Value %)

Chapter 3 Global Asthma and COPD Market Analysis
3.1 Global Asthma and COPD Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Asthma and COPD Market

Chapter 4 Global Asthma and COPD Market Analysis, by Drug Type, 2015-2025 (US$ Mn)
4.1 Introduction
4.2 Anti-inflammatory drugs
4.2.1 Corticosteroids
4.2.2 Anti-Leukotrienes
4.2.3 Monoclonal antibodies
4.3 Bronchodilator monotherapy
4.3.1 Short-acting beta2-agonist (SABAs)
4.3.2 Long-acting beta2-agonist (LABAs)
4.3.3 Anticholinergics
4.4 Combination drugs
4.5 Pipeline Analysis
4.5.1 Projected sales of Phase III Asthma/COPD Drugs estimated till 2025 (US$ Mn)
4.5.1.1 GSK/INNOVIVA Fluticasone Furoate + Umeclidinium + Vilanterol (COPD)
4.5.1.2 Novartis Fevipiprant (Asthma)
4.5.1.3 Astrazeneca Tralokinumab (Asthma)
4.5.1.4 AstraZeneca/Kyowa Hakko Kirin Benralizumab (Asthma)
4.5.1.5 AstraZeneca Budesonide + formoterol (COPD)
4.5.1.6 AstraZeneca Budesonide + formoterol + glycopyrrolate (COPD)
4.5.1.7 AB Science Masitinib (Asthma)
4.5.1.8 GlaxoSmithKline Vilanterol (COPD)
4.5.1.9 Regeneron/Sanofi Dupilumab (Asthma)
4.5.1.10 Sunovion Sun-101(COPD)
4.5.1.11 Theravance Biopharma/Mylan Revefenacin (COPD)
4.5.1.12 Others
4.5.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Asthma and COPD Market, By Geography, 2015-2025 (US$ Mn)
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, & Rest of APAC)
5.5 Latin America (Brazil, Mexico & Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 6 Company Profiles
6.1 Novartis AG
6.2 Merck & Co
6.3 Glaxosmithkline Plc
6.4 Boehringer Ingelheim Gmbh
6.5 Nycomed
6.6 Abbott Laboratories
6.7 AstraZeneca
6.8 Roche Holding AG
6.9 Teva Pharmaceutical Industries
6.10 Vectura Group
6.11 Pfizer Inc.

List of Figures

FIG. 1 Global Asthma and COPD Market: Research Methodology
FIG. 2 Global Asthma and COPD Market Share, by Product type, 2016 Vs 2025 (Value %)
FIG. 3 Global Asthma and COPD Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Asthma and COPD Market, by Geography
FIG. 5 Competitive Analysis: Key Players in Global Asthma and COPD Market
FIG. 6 Global HIV-1 Screening Tests Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global ELISA Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Rapid Tests Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Home Access Dried Blood Spots Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Western Blot Tests Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Indirect Immunofluorescence Assays (IFA) Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Line Immunoassays Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Radio-Immunoprecipitation Assays Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global P24 Antigen Market, 2015 – 2025 (US$ Mn)
FIG. 15 Global Qualitative PCR Test Market, 2015 – 2025 (US$ Mn)
FIG. 16 Global Viral Culture Market, 2015 – 2025 (US$ Mn)
FIG. 17 Global HIV-2 & Group O Diagnostic Tests Market, 2015 – 2025 (US$ Mn)
FIG. 18 Global Viral Load Tests Market, 2015 – 2025 (US$ Mn)
FIG. 19 Global CD4 Testing Market, 2015 – 2025 (US$ Mn)
FIG. 20 Global Early Infant Diagnostics Market, 2015 – 2025 (US$ Mn)
FIG. 21 Latin America Asthma and COPD Market, 2015 – 2025 (US$ Mn)
FIG. 22 Middle East & Africa Asthma and COPD Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Asthma and COPD Market, By Product Type 2015-2025 (US$ Mn)
TABLE 2 Global Antibody Tests Market, 2015-2025 (US$ Mn)
TABLE 1 Global HIV-1 Antibody Confirmatory Tests Market 2015-2025 (US$ Mn)
TABLE 1 Global Viral Identification testing Market 2015-2025 (US$ Mn)
TABLE 2 Global Asthma and COPD Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 3 North America Asthma and COPD Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 4 Europe Asthma and COPD Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Asia-Pacific Asthma and COPD Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Abbott Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 7 Abbvie Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 8 Alere Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 9 Apogee Flow Systems: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
TABLE 10 Beckman Coulter, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 11 Becton, Dickinson & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 12 BD Biosciences: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 Bio-Rad Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 14 BioMerieux: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 15 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 16 Cepheid: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 Chembio Diagnostic Systems: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Daktari Diagnostics: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Gilead Sciences: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Gilead Sciences: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 21 Merch & Co. Inc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 22 Mylan Inc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 23 Janssen Therapeutics: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

Frequently Asked Questions:

What is the size of Asthma And COPD Drugs Market?

The market for Asthma And COPD Drugs Market is expected to reach US$ 56,507.7 Mn By 2025.

What is the Asthma And COPD Drugs Market CAGR?

The Asthma And COPD Drugs Market is expected to see significant CAGR growth over the coming years, at 4.2%.

What is the Forecast period considered for Asthma And COPD Drugs Market?

The report is forecasted from 2017-2025.

What is the base year considered for Asthma And COPD Drugs Market?

The base year of this report is 2016.

Who are the major players in this market?

Novartis AG, Glaxosmithkline Plc., Boehringer Ingelheim Gmbh, Teva Pharmaceutical Industries are some of the major players in the global market.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN